Biomedical subjects
Publications and source records attributed to J McCaffrey.
Health-care executives need to eliminate "gut feel" decisions with a standardized approach to business planning, such as Baxter Healthcare Corp.'s Healthcare Business Planner. The author illustrates how University Hospitals of Cleveland used this model to determine the feasibility of an ambulatory center dedicated to systemic lupus erythematosus.
OBJECTIVE: To monitor and summarise activity of a Day Only Unit as a guide to management. METHOD: Attitude survey (patient questionnaire) of adults admitted to the Day Only Unit over a six week period, a telephone survey and an ongoing monthly record review of length of stay and complications. RESULTS: The level of "day only" activity is increasing and procedures affecting the quality of care of these patients are being improved. Patients not receiving pre-medications had fewer post-operative symptoms. The most frequent patient complaint related to the coldness of the ward.
Explore the source record for details and available documents.
Small or minor varicosities pose a considerable cosmetic problem to women afflicted with them. Previous methods of treatment have been either painful, or ineffective, or both. A simplified method of injection of these varices is described.
The microcirculation is an important but little understood part of the cardiovascular system. As new techniques have been developed, more accurate information has become available concerning the changes in the microcirculation in both health and disease. A review has been made of some of the more important facets of the microcirculation of particular interest to surgeons. Reference is made to basic physiology, especially the mechanisms controlling flow in the microcirculation. The significance of changes in small blood vessels in hypovolaemic, septic, and progressive shock is also discussed, and the role of platelet aggregation in shock states is explored.
A prospective study as been carried out on fifty patients with haemorrhoids treated by the Lord method who were followed up for at least four years. All patients were interviewed and examined regularly during the observation period. 75% of patients were rendered symptom-free or considerably improved. Apparently the long-term results of this method of treatment can be predicted from the results at eighteen months after operation.
A consecutive series of 118 patients was studied postoperatively by Doppler ultrasonic techniques and by either venography or radioiodinated fibrinogen. When using the latter diagnostic measures, 22 patients were shown to have deep venous thrombosis, an incidence of 18.6 per cent. The Doppler ultrasonic technique showed that 21 patients had deep venous thrombosis, an incidence of 17.7 per cent. When the patients diagnosed as having deep venous thrombosis by two separate methods were compared, it was shown that the Doppler technique gave two false-positive results and three false-negative results. It is concluded that this technique is accurate, and because of its convenience, lack of complications and ability to be repeated frequently, it should be the preferred screening technique for the diagnosis of postoperative deep venous thrombosis.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
The aim of this study was to determine the antitumor activity of pyrazoloacridine in patients with renal cell carcinoma. Eligible patients had advanced renal cell carcinoma with bidimensionally measurable disease, a Karnofsky performance status of at least 70, life expectancy of greater than three months, no prior treatment with chemotherapy, and no evidence of brain metastases. Patients were treated intravenously with 750 mg/m2 every three weeks. Twelve patients were enrolled in this study and all were evaluable for response and toxicity. Of the twelve patients, no major responses were achieved. Toxicity was mild, with three patients requiring a 20% dose reduction. At the dose and schedule used in this trial, pyrazoloacridine is inactive in renal cell carcinoma.